13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001596452
Total reported value
$131.7M
$131.7M
31 檔
42.4%
During the Q1 2025 filing period, Sivik Global Healthcare LLC (CIK: 0001596452) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $131.7M across 31 reported positions.
In Q1 2025, Sivik Global Healthcare LLC displayed an active expansion posture, initiating 31 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including XBI, BSX, THC) accounted for 42.4% of total reported equity market value during Q1 2025.
Top New Position Initiated
XBI
市值: $20.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 10.96% | — | +25.00% | |
| 2 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.45% | — | -9.09% | |
| 3 | THC | Tenet Healthcare CORP | Stock-Healthcare | 5.09% | — | +27.27% | |
| 4 | HCA | Hca Healthcare Inc | Stock-Healthcare | 4.67% | — | +25.00% | |
| 5 | LLY | Eli Lilly & Co | Stock-Healthcare | 4.02% | — | -40.00% | |
| 6 | MCK | Mckesson CORP | Stock-Healthcare | 4.00% | — | -26.67% | |
| 7 | DHR | Danaher CORP | Stock-Healthcare | 3.88% | — | +40.00% | |
| 8 | COR | Cencora Inc | Stock-Healthcare | 3.76% | — | — | |
| 9 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.75% | — | -6.67% | |
| 10 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.72% | — | — | |
| 11 | MDT | Medtronic plc | Stock-Healthcare | 3.64% | — | — | |
| 12 | SYK | Stryker CORP | Stock-Healthcare | 3.52% | — | -12.50% | |
| 13 | WAT | Waters CORP | Stock-Healthcare | 3.39% | — | +21.43% | |
| 14 | UHS | Universal Health Services-b | Stock-Healthcare | 3.30% | — | -13.33% | |
| 15 | HUM | Humana Inc | Stock-Healthcare | 3.29% | — | +15.00% | |
| 16 | BAX | Baxter International Inc | Stock-Healthcare | 3.24% | — | — | |
| 17 | ABT | Abbott Laboratories | Stock-Healthcare | 3.23% | — | -10.00% | |
| 18 | A | Agilent Technologies Inc | Stock-Healthcare | 3.16% | — | +42.86% | |
| 19 | EHC | Encompass Health CORP | Stock-Healthcare | 2.83% | — | +14.67% | |
| 20 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.78% | — | — | |
| 21 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 2.63% | — | — | |
| 22 | GILD | Gilead Sciences Inc | Stock-Healthcare | 2.42% | — | — | |
| 23 | CI | THE Cigna Group | Stock-Healthcare | 2.22% | — | +4.17% | |
| 24 | SNN | Smith & Nephew PLC -spon Adr | Stock-Other | 1.84% | — | -4.00% | |
| 25 | SEM | Select Medical Holdings CORP | Stock-Other | 1.81% | — | +33.33% | |
| 26 | AVTR | Avantor Inc | Stock-Healthcare | 1.75% | — | — | |
| 27 | SGRY | Surgery Partners Inc | Stock-Other | 1.61% | — | -37.50% | |
| 28 | WST | West Pharmaceutical Services | Stock-Healthcare | 1.51% | — | — | |
| 29 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.42% | — | -60.00% | |
| 30 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.69% | — | +100.00% | |
| 31 | ✓ | Put - Spy 100 @ 570 Exp 04/17/2025 | Stock-Other | 0.41% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 2 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 3 | THC | Tenet Healthcare CORP | — | NEW | New buy |
| 4 | HCA | Hca Healthcare Inc | — | NEW | New buy |
| 5 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 6 | MCK | Mckesson CORP | — | NEW | New buy |
| 7 | DHR | Danaher CORP | — | NEW | New buy |
| 8 | COR | Cencora Inc | — | NEW | New buy |
| 9 | ISRG | Intuitive Surgical Inc | — | NEW | New buy |
| 10 | CAH | Cardinal Health Inc | — | NEW | New buy |
| 11 | MDT | Medtronic plc | — | NEW | New buy |
| 12 | SYK | Stryker CORP | — | NEW | New buy |
| 13 | WAT | Waters CORP | — | NEW | New buy |
| 14 | UHS | Universal Health Services-b | — | NEW | New buy |
| 15 | HUM | Humana Inc | — | NEW | New buy |
| 16 | BAX | Baxter International Inc | — | NEW | New buy |
| 17 | ABT | Abbott Laboratories | — | NEW | New buy |
| 18 | A | Agilent Technologies Inc | — | NEW | New buy |
| 19 | EHC | Encompass Health CORP | — | NEW | New buy |
| 20 | AZNN | Astrazeneca Plc-spons Adr | — | NEW | New buy |
| 21 | NVO | Novo-nordisk A/s-spons Adr | — | NEW | New buy |
| 22 | GILD | Gilead Sciences Inc | — | NEW | New buy |
| 23 | CI | THE Cigna Group | — | NEW | New buy |
| 24 | SNN | Smith & Nephew PLC -spon Adr | — | NEW | New buy |
| 25 | SEM | Select Medical Holdings CORP | — | NEW | New buy |
| 26 | AVTR | Avantor Inc | — | NEW | New buy |
| 27 | SGRY | Surgery Partners Inc | — | NEW | New buy |
| 28 | WST | West Pharmaceutical Services | — | NEW | New buy |
| 29 | UNH | Unitedhealth Group Inc | — | NEW | New buy |
| 30 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 31 | ✓ | Put - Spy 100 @ 570 Exp 04/17/2025 | — | NEW | New buy |
According to official SEC Form 13F filings, Sivik Global Healthcare LLC reported a total U.S. public equity portfolio value of $131.7M across 31 disclosed positions in Q1 2025.
During Q1 2025, Sivik Global Healthcare LLC's top holdings by market value included XBI (11.0%)、BSX (5.5%)、THC (5.1%). The largest single position, XBI, represented 11.0% of total portfolio value.
In Q1 2025, Sivik Global Healthcare LLC made 31 total portfolio adjustments, initiating 31 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.